摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

Methyl (4-nitrophenyl) phenacyl phosphate

中文名称
——
中文别名
——
英文名称
Methyl (4-nitrophenyl) phenacyl phosphate
英文别名
——
Methyl (4-nitrophenyl) phenacyl phosphate化学式
CAS
——
化学式
C15H14NO7P
mdl
——
分子量
351.25
InChiKey
SJTNSCRHYMXYSR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.6
  • 重原子数:
    24
  • 可旋转键数:
    7
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.13
  • 拓扑面积:
    108
  • 氢给体数:
    0
  • 氢受体数:
    7

文献信息

  • TENSION-RELIEVING AGENTS FOR CILIARY MUSCLE
    申请人:Senju Pharmaceutical Co., Ltd.
    公开号:EP1224945A1
    公开(公告)日:2002-07-24
    Use of a chymase inhibitor in preventing and treating nearsightedness caused by the continuous tension of ciliary muscles makes it possible to achieve exact preventive and therapeutic effects with little side effects.
    使用糜蛋白酶抑制剂来预防和治疗因睫状肌持续紧张而引起的近视,可以达到确切的预防和治疗效果,而且副作用很小。
  • Prophylactic or threapeutic composition for ocular circulation disorders
    申请人:——
    公开号:US20040086537A1
    公开(公告)日:2004-05-06
    The conventional pharmacotherapy for diseases caused by a disturbance of ocular circulation, inclusive of glaucoma, comprises oral administration of steroids and other drugs and/or topical administration of &bgr;-adrenergic antagonists but these therapeutic regimens are invariably not effective enough but rather entail adverse reactions characteristic of the respective drugs used. This invention is characterized in that a chymase inhibitor is used for the prevention or treatment of diseases caused by a disturbance of ocular circulation and enables positive prophylaxis or therapy with reduced risks for side effects.
    对眼部循环障碍引起的疾病(包括青光眼)的传统药物治疗包括口服类固醇和其他药物和/或局部使用肾上腺素能拮抗剂,但这些治疗方案总是不够有效,反而会引起所用药物特有的不良反应。 本发明的特点在于,糜蛋白酶抑制剂可用于预防或治疗由眼部循环障碍引起的疾病,并能在降低副作用风险的情况下进行积极的预防或治疗。
  • Methods and Compositions for the Treatment of Hypertension and Gastrointestinal Disorders
    申请人:Talley John Jeffrey
    公开号:US20090054319A1
    公开(公告)日:2009-02-26
    The use of guanylin potentiating agents for treating various disorders, including hypertension as well as IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, chronic intestinal pseudo-obstruction, colonic pseudo-obstruction, Crohn's disease, duodenogastric reflux, dyspepsia, functional dyspepsia, nonulcer dyspepsia, a functional gastrointestinal disorder, functional heartburn, gastroesophageal reflux disease (GERD), gastroparesis, inflammatory bowel disease, irritable bowel syndrome, post-operative ileus, ulcerative colitis, chronic constipation, and disorders and conditions associated with constipation is described.
查看更多